Major capsid protein L1 of HPV16 was produced in a fused form in Escherichia coli using an inducible expression system. The protein formed insoluble aggregations (inclusion bodies) and the yield was more than 10% of total cell proteins. The inclusion bodies were isolated and solubilised with 8 M urea and the L1 proteins were purified by chromatographic separation. Following removal of the urea by gradual dialysis, the denatured L1 proteins spontaneously renatured and subsequently assembled into polymorphologic aggregations in vitro. Electron microscopy showed that the assembled material included structures resembling native empty capsids as well as incompletely formed capsids. After separation from the pool of polymorphologic structures by sucrose gradient sedimentation, the correctly formed virus-like particles (VLE. coliPs) were recognised by a HPV16 type-specific, conformational-dependent monoclonal antibody in an ELISA. This system offers not only a model for investigation of the intrinsic interactions that occur during L1 assembly, but also a potential route for convenient manufacture of highly purified VLP vaccines.
INTRODUCTION
Papillomaviruses are nonenveloped, double-stranded DNA viruses that infect a range of mammalian species (zur Hausen, 1994; Galloway and McDougall, 1989) . Of the 70 types that infect humans, papillomavirus type 16 (HPV16) is associated with the development of highgrade cervical intraepithelial neoplasia (CIN), which, if untreated, is likely to progress to cancer of the cervix (Bosch et al., 1995) . HPV16 is thus described as a``highrisk'' papillomavirus.
The inability to propagate papillomaviruses in vitro has hampered both the development of an attenuated virus vaccine and detailed molecular investigation of virus assembly. To this end, heterogeneic eukaryotic expression systems have been employed to generate empty viral capsids (virus-like particles (VLPs)) which spontaneously assemble from preparations of correctly folded recombinant capsid proteins. The major capsid protein, L1, which has a relative molecular weight of 55 kDa by reducing SDS±PAGE (Doorbar and Gallimore, 1987) , will assemble into VLPs (Hagensee et al., 1993; Kirnbauer et al., 1992 Kirnbauer et al., , 1993 Rose et al., 1993; Sasagawa et al., 1995; Heino et al., 1995) . Coexpression of L1 with the minor capsid protein, L2, which has a relative molecular weight of 72 kDa by reducing SDS±PAGE (Doorbar and Gallimore, 1987) , results in the incorporation of L2 into VLPs (Kirnbauer et al., 1993; Hagensee et al., 1993) , although the exact localisation of L2 into the VLP is not clear. The three-dimensional image of the assembled capsid is a T ϭ 7 icosahedral lattice, 55 nm in diameter, which is assembled from 72 pentamers of L1 (Baker et al., 1991) .
VLPs have not only provided a convenient model system for investigation of the structural properties of the capsid and the interactions of the capsid with the cell surface Roden et al., 1995; Volpers et al., 1995) , but they are also attractive candidates for a prophylactic vaccine against papillomavirus infection. The latter is supported by the demonstration that VLPs are highly immunogenic, eliciting an immune response that is very similar to the response elicited by native virions (Kirnbauer et al., 1992; Roden et al., 1994) . Furthermore, complete protection against canine oral papillomavirus (COPV) challenge was demonstrated in dogs, previously vaccinated with 20-g doses of COPV VLPs. This protection is likely to be mediated by the strong antibody response, generated by VLP vaccination (Suzich et al., 1995) .
Although VLPs generated in eukaryotic systems stimulate a strong immune response to native papillomavirus epitopes, thus eliciting neutralising antibodies in the host, production of VLPs in a prokaryotic system remains an attractive option for reasons of yield, ease of purification, and cost. A number of studies have reported successful expression of HPV L1 proteins in bacteria (Banks et al., 1987; Doobar and Gallimore, 1987; Li et al., 1987; Thompson and Roman, 1987; Jenison et al., 1988) but until recently, it appeared that such system could only generate incorrectly folded protein with consider-ably less immunogenicity than properly assembled particles. In this report, we describe the expression of HPV16 L1 in the form of insoluble inclusion bodies (IBs) and the subsequent renaturation and self-assembly of this protein into virus-like particles (termed VLE. coliPs) that not only morphologically resemble those particles (termed VLBacPs) derived via expression by baculovirus recombinants, but are also recognised by HPV16 conformational-dependent antibody. This system could offer practical advantages over those in which VLPs are produced directly within the host, in that more rigorous purification methods could be used to generate material free of contamination.
RESULTS

Expression and characterisation of HPV16 L1 expressed in E. coli
The induction of HPV16 L1 expression in IPTG-treated cultures of pET16L1-transformed E. coli HMS174 (DE3) (Fig. 1 ) was analysed by reducing SDS±PAGE. As shown in Fig. 2A , a protein of approximately 60 kDa mass accumulated in cell lysates of IPTG-treated cultures ( Fig.  2A, lane 2) . This protein was not detected in uninduced cultures ( Fig. 2A, lane 1) . The identity of the 60-kDa protein as L1 was confirmed by Western blotting using the anti-L1 monoclonal antibody Camvir 1. The antibody reacted strongly to the 60-kDa protein, as well as to some lower molecular weight proteins (Fig. 2B , lane 2) which may result from the degradation of the full-length L1 or premature termination of translation. Cell lysates from uninduced cultures were not recognised by this antibody (Fig. 2B, lane 1) .
The observed molecular weight is approximately 5 kDa greater than previously determined, due to the fusion of the coding sequence at the amino terminus to 31 amino acids including a 24-amino-acid leader sequence, pelB, and at the carboxyl terminus to six histidine residues (His tag). To confirm that the L1 was indeed fused to these sequences, the 60-kDa protein was subjected to N-terminal amino acid analysis. The result showed that the first 5 amino acids of the protein are Met-Lys-TyrLeu-Leu, which is identical to the N-terminal sequence of pelB leader encoded by the expression vector pET-22b (Novagen). In addition, Western blotting (Fig. 3) confirmed that the 60-kDa L1 protein is tagged by multiple histidine residues. The anti His-tag monoclonal antibody, RGS His (QIAGEN), recognised the 60-kDa L1 protein in the lysate of IPTG-induced E. coli cells (Fig. 3 , lane 2), but did not recognise the 60-kDa proteins in the lysate of uninduced E. coli cells (Fig. 3, lane 1) or the full-length L1 proteins from denatured VLBacPs (Fig. 3, lane 3) .
The yield of this 60-kDa fusion L1 protein expressed in E. coli cells after IPTG induction was estimated by densitometric scanning following SDS±PAGE and Coomassie blue staining of cell total extracts. L1 was determined as comprising 10±15% of the total cellular protein. The overexpressed L1 was accumulated in the cells as IBs which could be visualised by electron microscopy (data not shown). IBs were isolated as described under Materials and Methods and the insoluble pellet divided into four and treated with 8.0, 6.0, 4.0, and 2.0 M urea, respectively. As shown in Fig. 4 , none of the supernatants generated during the isolation of IBs contained the expressed protein (Fig. 4, lanes 1±3 ), whereas L1 was effectively solubilised in the 8.0 M urea (Fig. 4, lane 4) , partially solubilised in 6.0 and 4.0 M urea (Fig. 4 , lanes 5 and 6), and insoluble in 2.0 M urea (Fig. 4, lane 7) . This indicated that L1, expressed in E. coli as IBs, is highly insoluble.
Purification of the insoluble L1 protein
The accumulation of prokaryotically expressed L1 in IBs facilitated its purification as the IBs could be isolated by the series of centrifugation and wash steps outlined under Materials and Methods. This resulted in a preparation that was observed by reducing SDS±PAGE as being partially pure (Fig. 5 , lane 1). Subsequent cation exchange chromatography using CM±Sepharose fast flow, in the presence of 8 M urea under weakly acidic conditions (pH 6.8), resulted in further purification of L1. No L1 was eluted during the application of the L1 or during the wash step, which used 100 mM NaCl to remove weakly bound host cell proteins (Fig. 5, lanes 2±3) . L1 was eluted from the column with 500 mM NaCl (Fig. 5 , lane 4).
In vitro self-assembly of purified L1 protein
The conditions applied to solubilise and purify L1 resulted in the protein being denatured and reduced. In order to promote the refolding of purified L1 to its native conformation and the subsequent self-assembly of L1 into VLPs, the denaturant was completely removed by a stepwise dialysis procedure as described under Materials and Methods. Examination of the final preparation of renatured L1 by electron microscopy under negative staining (Fig. 6 ) demonstrated that L1 assembled into incomplete and complete VLPs during the dialysis procedure. The completely assembled VLE. coliPs were 50±60 nm in diameter and morphologically indistinguishable from VLBacPs ( Fig. 6, insert) . Examination of the VLE. coliPs after 2 months storage at 4°C in buffer A demonstrated that the particles are conformationally stable.
To analyse the efficiency with which the renatured L1 self-assembles in vitro into VLE. coliPs via the dialysis process, a 10±55% sucrose gradient sedimentation was used to separate VLE. coliPs from polymorphological structures in the dialysed preparation as described under Materials and Methods. Fractions were analysed by Western blotting with anti-L1 monoclonal antibody Camvir 1. A small percentage of the L1 protein banded at the higher density region, while most of the proteins remained at top of the gradient (data not shown), suggesting that the L1 protein was present predominantly in an unassembled state in the dialysed preparation. Further, the HPV16 conformational-dependent monoclonal antibody H16 V5 was used in an ELISA as a direct test of the fractions which contained completely formed VLE. coliPs (Fig. 7A) . It was found that only the samples from the bottom part of the gradient (fractions 21±25) showed a , were applied to a CM±Sepharose column equilibrated at pH 6.8 and the unbound material was collected (lane 2). Following the removal of weakly bound proteins (lane 3) by a low-salt wash (100 mM NaCl), L1 was eluted from the column with buffer containing 500 mM NaCl (lane 4). The protein molecular weight markers were loaded adjacently (lane M). detectable signal. This observation suggests that correctly formed particles were present in these fractions.
To quantify the VLE. coliPs which were isolated by the sedimentary centrifugation, fractions 21±25 from each of the sucrose gradients were diluted, centrifuged, and used to react with antibody H16 V5 in an ELISA. In the same assay, VLBacPs were used in different amounts as quantitive controls (Fig. 7B) . It was found that the wells coated with collected materials of fractions 21±25 had developed an optical density (OD 450 nm) value of 0.30± 0.55, which was relevant to the OD 450 nm value of about 20±50 ng of VLBacPs to H16 V5. As approximately 0.1 mg of dialysed L1 protein was initially subjected to each of the sucrose gradients, 20±50 ng was determined to be assembled into VLE. coliPs, thus giving an efficiency of 0.02±0.05%. The fact that these VLE. coliPs reacted with H16 V5, a well-characterised conformational-dependent HPV16-specific neutralising antibody, demonstrates that a type-specific conformational epitope is located on these structures.
DISCUSSION
This report has described the in vitro assembly of HPV16 VLE. coliPs following the solubilisation of bacterially expressed HPV16 L1 in 8 M urea and subsequent purification and renaturation. Electron microscopy of the negatively stained renatured preparation confirmed the presence of VLPs with a relatively uniform size of 50±60 nm in diameter. This observation indicates that the in vitro assembled VLPs resemble, in morphology, VLBacPs assembled in eukaryotic baculovirus systems. Further, we also show that these in vitro assembled particles display a conformational/neutralisisng epitope(s).
The assembly in vitro of bacterially expressed viral structural proteins into VLPs has been demonstrated in several previous studies, including polyoma VP1 (Salunke et al., 1986) , hepatitis B core antigen (Stahl et al., 1982) , and very recently the HPV11 L1 protein (Li et al., 1997) . In these studies, the viral structural proteins expressed in bacterial cells were soluble and associated into pentameric capsomers or capsid-like particles within the bacterial compartment. However, this was not the case with the bacterially expressed HPV16 L1 in this study. Examination of IPTG-induced cells by thin-section electron microscopy did not reveal any VLP structures or any lattice arrangements which would imply the presence of capsomeric assemblies (data not shown). In fact, the L1 proteins accumulated in the cell as insoluble aggregates, IBs, which could only be solubilised with high concentrations of denaturant. Therefore, a denaturation±renaturation process was employed to restore the native folding of the protein and thus to promote the assembly of L1 into VLE. coliPs.
In this study, VLE. coliPs self-assembled in vitro from a fusion protein of L1. Fusion of the L1 N-terminus to the pelB leader sequence was thought to enhance the stability of the foreign protein with regard to enzymatic degradation and to effect secretion of the protein into the periplasmic space. However, in this case, L1 accumulated within the cytoplasm as IBs. The fusion of the C-terminus to the positively charged His tag residue was undertaken to allow the purification of L1 with ion-exchange chromatography. In addition to the fused L1 protein described above, we have also prepared unfused L1 protein from the same bacterial expression system and analysed this for the capacity of self-assembly in vitro. Briefly, a similar profile was observed to that of pET16L1-expressed fusion L1 protein; thus the protein was expressed at a high level but accumulated as IBs. It is unclear whether the unfused L1 protein could be selfassembled into a better yield of VLE. coliPs under the denaturation±renaturation process, as it was very difficult to purify this neutral-charged protein from bacterial contamination.
After a range of conditions were examined for effective renaturation of L1 protein in vitro, a number of factors were identified that affect L1 renaturation and VLP assembly. First, the purity of the L1 protein was crucial, as bacterial contaminants interfere with renaturation. To this end, an ion-exchange chromatography step was employed prior to the renaturation process. Second, the concentration of L1 during the renaturation was also important, as misfolding and intermolecular aggregation occur at high protein concentrations; thus, the renaturation was performed at a protein concentration of about 0.1 mg/ml. Third, the rate at which the denaturant and reducing agent is removed from the preparation was also important in encouraging folding to the native conformation. In this study, it was found that a gradual reduction in urea and DTT concentrations by four dialysis steps could minimise L1 aggregation during renaturation. In addition, renaturation was dependent on pH and ionic strength. The selected conditions for the renaturation and assembly of L1 in this study were at pH 8.0 and under a low-salt concentration (100 mM NaCl).
Although the above conditions are essential for in vitro assembly of L1 into VLE. coliPs consistently, the yield of correctly formed VLE. coliPs was low. A possible explanation may be the inefficient reformation of the correct disulfate linkages following denaturation and renaturation. It has been known that there are 12 cysteine FIG. 7 . A 10±55% sucrose sedimentation of VLE. coliPs. The gradient was fractioned and VLE. coliPs were detected using the conformational-specific monoclonal antibody H16 V5 in an ELISA (A). Fractions 21±25 were collected, diluted, and centrifuged to pellet VLE. coliPs. Particles in each of the pellets (p1±p3) were tested with H16 V5 in an ELISA (B), together with a range of concentration of VLBacPs as a quantitive control. residues in the L1 amino acid sequence and L1 is probably a highly disulfide-bonded protein. As the rate and yield of correct disulfide bond formation by air oxidation generally are low (Ahmed et al., 1975) , refolding of denatured L1 protein by a conventional dialysis procedure over a 1-to 2-day period may not be sufficient time for the molecule to achieve a stable native conformation. In this case, the yield of VLE. coliPs could possibly be improved by enhancing disulfate bond formation. Several methods that enhance this during protein renaturation have been described (Wetlaufer et al., 1987; DiBella et al., 1995) and the work is in progress to improve the yield of HPV16 VLE. coliPs based on these studies.
The amino acid residues or domains of HPV16 L1 essential for capsid assembly have not been fully elucidated. It has been shown previously that the aspartic acid residue at position 202 is necessary for VLP formation by HPV16 L1 expressed via a baculovirus recombinant (Kirnbauer et al., 1993) . The HPV16 L1 DNA used in the present study was derived from the HPV16 episomes present in W12, a cell line established from a CIN I lesion. Sequencing of this full-length L1 DNA identified three nucleotide changes compared to the original prototype (Seedorf et al., 1985) . Two of these nucleotide changes are the amino acid codons histidine to aspartic acid at position 202 and threonine to alanine at position 266. These nucleotide changes have been observed before in HPV16 genomes derived from low-grade clinical biopsies (Kirnbauer et al., 1993; Pushko et al., 1994) . The third nucleotide substitution, nt 5962 T to C, does not result in a change in amino acid. These data suggest that the L1 ORF in the HPV16 in W12 cells encodes the wild-type L1 protein. This is supported by the ability of W12 cells to support permissive viral replication (Sterling et al., 1990) and by the high efficiency with which baculovirus-expressed W12 HPV16 L1 protein assembles VLBacPs (data not shown).
The pET16L1 construct expresses L1 as a fusion protein with the coding sequence fused at the amino and carboxyl termini to sequences encoded by the expression vector. However, we show in this report that this protein can self-assemble, generating VLE. coliPs which display conformational type-specific epitopes. Potentially these structures are highly immunogenic and could be useful in the development of safe readily purified HPV16 vaccine.
MATERIALS AND METHODS
Construction of the prokaryotic expression vector pET16 L1
The L1 coding region, exclusive of the translation start codon ATG (second) and stop codon TAA, was amplified by the polymerase chain reaction (PCR) from the keratinocyte cell line W12 (Stanley et al., 1989) , in which multiple copies of the entire HPV16 genome are maintained episomally. To maximise full-length protein expression by avoidance of transcription termination (Earl et al., 1990; Zhou et al., 1991) , the amplification method of overlap extension was used to effect mutagenesis of a region of seven thymidylate bases at positions 6377± 6383 (inclusive) to TTCTTCT, thus maintaining the amino acid coding sequence. In addition, a region of six adenylate bases at positions 7139±7144 (inclusive) was changed to AAGAAG, again conserving the amino acid sequence, by including these base changes in the reverse amplification primer. Thus, a 753-base-pair (bp) fragment encompassing the 5Ј half of the L1 coding sequence was amplified using the following pair of primers, the forward primer incorporating a BglII restriction site (underlined). Forward primer: 5Ј GATCAGATCT-GTCTCTTTTGGCTGCCTAGTGAGGCC 3Ј; reverse primer: 5Ј CGTAAATAGAAGAATAAGCTGTCG 3Ј. A 798-bp fragment encompassing the 3Ј half of the L1 coding region was amplified using the following pairs of primers, the reverse primer incorporating a NotI restriction site (underlined). Forward primer: 5Ј CGACAGCTTATTCTTC-TATTTACG 3Ј; reverse primer: 5Ј CTAGCGGCCGC-CAGCTTACGCTTCTTGCGTTTAGC 3Ј. The two amplification products were purified and used as a target for a final amplification reaction using the flanking forward and reverse primers incorporating a BglII and a NotI site, respectively. The full-length, mutagenised L1 coding sequence thus amplified was cloned into a pGEM-T PCR cloning vector (Promega) from which it was excised and ligated into the bacterial expression vector pGW046, a derivative of pET-22b (Novagen) that confers kanamycin resistance, which had been digested with BamHI and NotI. This created the L1 expression vector pET16L1 (Fig.  1) . As indicated earlier, L1 coding sequence in the vector did not include the translational start and stop codons; thus, protein expression is initated from the start codon of the vector-encoded pel B leader sequence and terminated after the 3Ј His tag, thereby resulting in a fused L1 protein. The clone was confirmed by DNA sequencing using the T7 sequencing kit (Pharmacia).
Expression of HPV16 L1 protein and immunoblot detection
Escherichia coli HMS174 (DE3) cells (Novagen), transformed with pET16L1, were cultured in the soya-based medium 2YS (17.8 g/liter vegetable peptone, 11.1 g/liter yeast extract, 5.6 g/liter NaCl) until the absorbance of the culture at 600 nm against uninoculated medium was 1.0±1.2 units. L1 expression was then induced by the addition of isopropyl-␤-D-thiogalactopyranoside (IPTG) to a concentration of 0.4 mM. After a 2-h induction period, the cells were harvested by centrifugation at 5000 g for 15 min at 4°C.
L1 expression was monitored by reducing SDS±PAGE of total cell lysates containing 20±30 g protein and staining with Coomassie brilliant blue R (Sigma). For further confirmation, cell lysates were electroblotted onto Hybond-C membrane (Amersham Inc.) and the L1 protein was immunodetected using the anti-HPV16 L1 monoclonal antibody Camvir 1 (McLean et al., 1990) in combination with the secondary antibody, peroxidaseconjugated rabbit anti-mouse IgG (DAKO). The reaction signals were detected using the chemiluminescent ECL detection kit (Amersham Inc.).
Purification of L1 protein from inclusion bodies
A 500-ml induced culture of pET16L1-transformed E. coli HMS174 was harvested by centrifugation as described previously and the cells were washed with phosphate-buffered saline (PBS), pelleted by centrifugation, and stored at Ϫ70°C until required. Once thawed, the cell pellet was resuspended in buffer A [50 mM Tris±Cl (pH 8.0), 1 mM EDTA, 1 mM dithiothreitol (DTT), 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 100 mM NaCl] containing 20% (w/v) sucrose and 1 mg/ml lysozyme. After the lysis reaction was incubated for 30 min on ice, the insoluble material was collected by centrifugation at 12,000 g for 15 min at 4°C. The insoluble pellet was then washed, first by buffer A containing 10 mM MgCl 2 , then by buffer A containing 1% (v/v) Triton X-100, and finally by buffer A containing 2 M urea. Between each wash the insoluble material, which is predominantly L1 protein in IBs, was pelleted by centrifugation at 12,000 g for 15 min at 4°C. The isolated IBs were solubilised in buffer B (50 mM Tris±Cl, pH 8.0, 5 mM EDTA, 10 mM DTT, 8 M urea). The solubilisation process was carried out at room temperature for 1 h with gentle agitation. Any remaining insoluble debris was removed by centrifugation at 15,000 g for 15 min.
The solubilised L1 protein was applied to a CM± Sepharose fast-flow (Pharmacia) column, previously equilibrated with buffer C (50 mM Tris±Cl, pH 6.8, 5 mM EDTA, 10 mM DTT, 8 M urea). The column was then washed with buffer C containing 100 mM NaCl to remove unbound and weakly bound contaminants prior to elution of L1 with buffer C containing 500 mM NaCl. Proteins in each collected fraction were analysed by reducing SDS± PAGE and Coomassie blue staining.
Renaturation of L1 protein and sedimentary purification of VLE. coliPs
To renature the purified L1 proteins, the high concentrations of denaturant (8 M urea) and reducing reagent (10 mM DTT) were removed by a stepwise dialysis procedure whereby four 6-h dialysis steps were performed against buffer A containing 4.0, 2.0, 1.0, and 0 M urea. All steps in the renaturation of L1 protein were performed at 4°C. Any aggregated material formed during the dialysis was removed by centrifugation at 20,000 g for 20 min.
The clarified supernatant was stored at 4°C until required.
Further purification of correctly formed VLE. coliPs was achieved by centrifugation in a 10±55% sucrose gradient in buffer A. One milliliter of dialysed protein supernatant, at 0.1 mg/ml concentration, was loaded onto the gradient (4 ml) and centrifuged at 4°C in a SW55Ti rotor at 188,000 g for 2 h. The gradient was then fractionated into 25 aliquots (approximately 200 l each) from the top of the centrifuge tube. The fractions were then analysed by immunoblotting and enzyme-linked immunosorbent assay (ELISA), as described in Section 7.
Preparation of VLBacPs from baculovirusexpressed L1
The L1 DNA of HPV16 was amplified by PCR from the W12 cell line (described previously) using primers which incorporate BglII restriction sites (underlined) as follows: Forward primer: 5Ј-GCTGCAAGATCTATGTCTCTTTG-GCTGCCTAGT-3Ј; reverse primer: 5Ј-TCGAGCAGATCTT-TACAGCTTACGTTTTTTGCG-3Ј. The approximately 1.6-kilobase (kb) amplification product was digested with BglII and ligated into BamHI-digested pBacPAK1 (Clontech) to give the recombinant pBac16L1. The L1 coding sequence in pBac16L1 was confirmed by DNA sequencing using the T7 sequencing kit (Pharmacia). pBac16L1 and AcM-NPV DNA (BacPAK6; Clontech) were then used to cotransfect into insect Sf21 cells and the recombinant baculoviruses plaque purified (Summers and Smith, 1987) and further expanded by multiple cycles of cell infection. The infection of Sf21 cells with the resulting recombinant baculovirus and the purification of VLBacPs from infected cells were performed as described previously (Kirnbauer et al., 1993) .
Electron microscopy
The VLP preparation containing 100±300 g/ml protein was dropped in 5-to 10-l quantities onto glow-discharged carbon-coated grids and allowed to absorb for 2 min. Following of the removal of unabsorbed materials from the grid, the material on each grid was stained with 2% (w/v) potassium phosphotungstic acid (pH 6.8) and viewed with a Philip CM 100 transmission electron microscope.
ELISA
The identification and quantification of VLE. coliPs in the sucrose fractions was achieved by ELISA testing with the monoclonal antibody H16 V5 which recognises only the native, nondenatured HPV16 VLPs (Christensen et al., 1996) . In brief, 20 l of the sample was taken from each of the 25 fractions and diluted 1:10 in PBS and used to coat a 96-well ELISA plate (Nunc). As a negative control, the wells were coated only with PBS, but the same procedure was applied to the test samples. Ad-sorption of the applied protein to the plate was effected by incubating at 4°C for 16 h. After the plate was washed with PBS, the blocking buffer, i.e., 5% (w/v) dry milk in PBS/0.1% Tween 20 (PBST), was applied to the wells and the plate was incubated for 1 h at ambient temperature. H16 V5 was diluted 1:50 in blocking buffer and applied to the plates, which were then incubated at 37°C for 1 h. After the plates were washed with PBST, the secondary antibody, peroxidase-conjugated rabbit anti-mouse IgG (DAKO), was used at a 1:2000 dilution. The unbound antibody was removed by washing the plate with PBST after incubating the plate for 1 h at 37°C. The bound antibody was then stained using substrate, i.e., 4 mg of o-phenylenediamine in 5 ml of 0.2 M Na 2 PO 4 plus 0.1 M citric acid with 2 l 30% H 2 O 2 , and the signal was developed at room temperature for 20 min under dark conditions. The absorbance at 450 nm of each well was then measured with a Dynatech MR5000 automated plate reader.
In order to quantify the efficiency of the VLE. coliP assembly, sucrose fractions which reacted positively with the H16 V5 antibody in the ELISA were combined and then diluted 1:5 with PBS for a further centrifugation at 188,000 g for 2 h at 4°C. The pellet was gently resuspended in 100 l of PBS and used to coat the ELISA plate. As a quantity control, HPV16 VLBacPs at 5, 10, 50, and 100 ng in 100 l of PBS were coated onto the same plate and ELISA was carried out as previously described.
